Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 2
1990 2
1991 2
1992 3
1993 4
1994 7
1995 9
1996 14
1997 4
1998 5
1999 3
2000 12
2001 4
2002 17
2003 17
2004 17
2005 22
2006 13
2007 10
2008 12
2009 13
2010 12
2011 8
2012 13
2013 19
2014 17
2015 19
2016 11
2017 12
2018 11
2019 21
2020 24
2021 28
2022 21
2023 24
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

384 results

Results by year

Filters applied: . Clear all
Page 1
Management of adverse effects/toxicity of ibrutinib.
Paydas S. Paydas S. Crit Rev Oncol Hematol. 2019 Apr;136:56-63. doi: 10.1016/j.critrevonc.2019.02.001. Epub 2019 Feb 10. Crit Rev Oncol Hematol. 2019. PMID: 30878129 Review.
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.
Sezer A, Kilickap S, Gümüş M, Bondarenko I, Özgüroğlu M, Gogishvili M, Turk HM, Cicin I, Bentsion D, Gladkov O, Clingan P, Sriuranpong V, Rizvi N, Gao B, Li S, Lee S, McGuire K, Chen CI, Makharadze T, Paydas S, Nechaeva M, Seebach F, Weinreich DM, Yancopoulos GD, Gullo G, Lowy I, Rietschel P. Sezer A, et al. Among authors: paydas s. Lancet. 2021 Feb 13;397(10274):592-604. doi: 10.1016/S0140-6736(21)00228-2. Lancet. 2021. PMID: 33581821 Clinical Trial.
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer.
Kahraman S, Erul E, Seyyar M, Gumusay O, Bayram E, Demirel BC, Acar O, Aksoy S, Baytemur NK, Sahin E, Cabuk D, Basaran G, Paydas S, Yaren A, Guven DC, Erdogan AP, Demirci U, Yasar A, Bayoglu İV, Hizal M, Gulbagci B, Paksoy N, Davarci SE, Yilmaz F, Dogan O, Orhan SO, Kayikcioglu E, Aytac A, Keskinkilic M, Mocan EE, Unal OU, Aydin E, Yucel H, Isik D, Eren O, Uluc BO, Ozcelik M, Hacibekiroglu I, Aydiner A, Demir H, Oksuzoglu B, Cilbir E, Cubukcu E, Cetin B, Oktay E, Erol C, Okutur SK, Yildirim N, Alkan A, Selcukbiricik F, Aksoy A, Karakas Y, Ozkanli G, Duman BB, Aydin D, Dulgar O, Er MM, Teker F, Yavuzsen T, Aykan MB, Inal A, Iriagac Y, Kalkan NO, Keser M, Sakalar T, Menekse S, Kut E, Bilgin B, Karaoglanoglu M, Sunar V, Ozdemir O, Turhal NS, Karadurmus N, Yalcin B, Nahit Sendur MA. Kahraman S, et al. Among authors: paydas s. Future Oncol. 2023 Mar;19(10):727-736. doi: 10.2217/fon-2022-1287. Epub 2023 May 3. Future Oncol. 2023. PMID: 37133230
Coexistência de osteoartropatia hipertrófica e mielofibrose.
Kelle B, Yıldız F, Paydas S, Bagır EK, Ergin M, Kozanoglu E. Kelle B, et al. Among authors: paydas s. Rev Bras Reumatol. 2014 Dec 23:S0482-5004(14)00247-2. doi: 10.1016/j.rbr.2014.11.003. Online ahead of print. Rev Bras Reumatol. 2014. PMID: 25577488 Free article. Portuguese.
Commentary.
Paydas S. Paydas S. J Neurosci Rural Pract. 2012 Jan;3(1):100. J Neurosci Rural Pract. 2012. PMID: 22346214 Free PMC article. No abstract available.
Hepatitis C virus and lymphoma.
Paydas S. Paydas S. Crit Rev Oncol Hematol. 2015 Mar;93(3):246-56. doi: 10.1016/j.critrevonc.2014.10.008. Epub 2014 Oct 22. Crit Rev Oncol Hematol. 2015. PMID: 25457774 Review.
Doxazosin overdosage.
Gokel Y, Dokur M, Paydaş S. Gokel Y, et al. Among authors: paydas s. Am J Emerg Med. 2000 Sep;18(5):638-9. doi: 10.1016/s0735-6757(00)90109-8. Am J Emerg Med. 2000. PMID: 10999589 No abstract available.
384 results